Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals develops clinical-stage immunotherapy medicines built around rose bengal sodium, a synthetic small molecule in the halogenated xanthene family. News about PVCT centers on its PV-10 and PV-305 formulations, research publications, preclinical disease models, and clinical-program activity across oncology, dermatology, and ophthalmology.
Recurring updates also cover VisiRose, the company’s ocular-therapeutics subsidiary, and rose bengal photodynamic antimicrobial therapy for infectious keratitis and other eye infections. Additional company announcements address proof-of-concept work in wound healing, infectious disease, tissue repair, hematology, and vaccine-adjuvant research, along with annual-meeting and other public-company governance matters.
Provectus (OTCQB: PVCT) presented data from an ongoing clinical trial of PV-10 for treating metastatic neuroendocrine tumors at the ESMO Congress (Sept 16-21, 2021). The trial involved 12 patients, showing an objective response rate of 42% and a disease control rate of 83%. Median progression-free survival was 9.2 months, with overall survival at 22.5 months. Notable adverse effects included injection site pain in 75% of patients. The CEO expressed optimism regarding PV-10’s potential in refractory cases and future Phase 2 testing. Data collection is expected to finalize in Q4 2021.
Provectus (OTCQB: PVCT) announced the presentation of data from an ongoing clinical trial of PV-10, an investigational cancer immunotherapy for neuroendocrine tumors (NET) metastatic to the liver, at the European Society for Medical Oncology Congress from September 16-21, 2021. The abstract, titled “Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms” (#4354), highlights PV-10's potential in treating this challenging cancer type.
Provectus (PVCT) announced promising preclinical data on its investigational cancer treatment, PV-10, presented at the ASCO 2021 Annual Meeting. The study focused on oral delivery of PV-10 for adult solid tumors, demonstrating autophagic cell death across various cancer cell lines, including breast, colorectal, head and neck, and testicular cancers. Key findings revealed that testicular cancer cells showed the highest sensitivity to PV-10. The research led by Aru Narendran, MD, PhD, highlights the potential for PV-10 to selectively target certain cancers while maintaining a wide therapeutic window.
Provectus (OTCQB: PVCT) reported promising preliminary data from its Phase 1 clinical trial of PV-10 for treating neuroendocrine tumors metastatic to the liver. The findings, presented at the ASCO 2021 Annual Meeting, showed an 83% disease control rate (DCR), with a median progression-free survival (PFS) of 9.2 months and median overall survival (OS) of 22.5 months. Among the 12 heavily pre-treated patients, 42% achieved a partial response. The trial indicated a strong immune response, with mild side effects and no major safety concerns reported.
Provectus (OTCQB: PVCT) announced a $2.5 million funding commitment from the State of Tennessee to develop animal health drug products in collaboration with local universities. The initiative will focus on oncology, hematology, and dermatology treatments for animals, utilizing Provectus' halogenated xanthene platform. Key milestones include prior studies in solid tumors in companion animals and human clinical trials. Board members express gratitude towards the state for supporting innovation and aim to address local health needs through this partnership.
Provectus (OTCQB: PVCT) announced the acceptance of two abstracts for the ASCO 2021 Annual Meeting, showcasing the potential of PV-10, an investigational cancer immunotherapy. The first abstract details a Phase I clinical trial focused on intralesional PV-10 administration for metastatic neuroendocrine tumors, conducted at The Queen Elizabeth Hospital in Australia. The second abstract presents preclinical research on the oral administration of PV-10 for treating high-risk adult solid tumors. Both presentations highlight the ongoing research and potential applications of PV-10 in cancer therapy.
Provectus (OTCQB: PVCT) announced a published study on PV-10, showing a 46% complete response rate and 86% overall response rate in treating in-transit melanoma lesions in 48 patients. Conducted at the Melanoma Institute Australia, the study highlights a median age of 75.1 years for participants and significant overall survival rates of 77% and 56% at 12 and 24 months, respectively. This publication marks the fifth study of PV-10, emphasizing its potential as a low-toxicity treatment option for patients with limited alternatives.
Provectus (OTCQB: PVCT) announced that the USPTO has allowed its patent application 16/678,133, covering the use of intralesional PV-10 in combination with immune checkpoint inhibitors for adult solid tumor cancers. This includes melanoma, breast, liver, prostate, and lung cancers. The allowed patent is the fourth continuation of a foundational cancer treatment patent granted in 2015. Vice Chair Dominic Rodrigues highlighted that this new patent strengthens their oncology drug development program, focusing on the combination therapies that enhance immune response against solid tumors.
Provectus announced that the USPTO has allowed patent application 16/412,872, which pertains to the use of PV-10, an injectable formulation of rose bengal disodium, for treating relapsed and refractory pediatric solid tumor cancers. This patent represents the initial intellectual property from the company's collaboration with Dr. Aru Narendran at the University of Calgary. The patent supports both monotherapy and combined treatments with immune checkpoint blockade or radiotherapy. Provectus aims to further develop its intralesional oncology drug program to enhance cancer treatment options.
Provectus (OTCQB: PVCT) announced that H. Lee Moffitt Cancer Center will present non-clinical data on PV-10, an injectable cancer immunotherapy using rose bengal disodium (RBD), at the SITC 2020 Annual Meeting (Nov 9-14, 2020). The presentation will include research on the drug's efficacy, especially in combination with chemotherapy for pancreatic cancer. PV-10 aims to induce immunogenic cell death in tumors through lysosome disruption. This follows previous positive findings on RBD's immune responses in various cancers, with ongoing clinical studies for adult and pediatric solid tumor cancers.